Disease · MONDO_0005070

neoplasm

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. neoplasm. Diseases, record MONDO_0005070. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005070

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: neoplasm; Open Targets
Open Targets ID: MONDO_0005070; Open Targets
Other names: disease of cellular proliferation, neoplasia, neoplasm (disease), neoplastic disease, neoplastic growth, tumor, tumor disease, tumour, tumour disease; Open Targets
Disease Ontology: DOID:14566; Disease Ontology
MeSH: D009369; MeSH
NCI Thesaurus: C3262; NCI Thesaurus
Highest stage of its drugs: Approval, for 411 of its 1,442 drugs, from ATC, DailyMed, EMA Human Drugs, FDA and PMDA; Open Targets

Drugs1,442

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Approval	ATC	27	26	25	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Approval	ATC	21	20	18	Drugs and targets
GEMCITABINE	CHEMBL888	Small molecule	Approval	ATC	17	16	15	Drugs and targets
NIVOLUMAB	CHEMBL2108738	Antibody	Approval	ATC	17	16	15	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Approval	ATC	13	12	12	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Approval	ATC	13	12	12	Drugs and targets
DOCETAXEL	CHEMBL3545252	Small molecule	Approval	ATC	13	12	12	Drugs and targets
TORIPALIMAB	CHEMBL4297843	Antibody	Approval	ATC	13	11	10	Drugs and targets
IRINOTECAN	CHEMBL481	Small molecule	Approval	ATC	12	11	9	Drugs and targets
FLUOROURACIL	CHEMBL185	Small molecule	Approval	ATC	13	10	7	Drugs and targets

1 to 10 of 1,442

See all 1,442 drugs

Targets490

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
EGFR	Epidermal growth factor receptor	30	Epidermal growth factor receptor erbB1 binding agent; Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor erbB1 negative allosteric modulator; Epidermal growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/1956	Drugs and targets
TUBA1A	Tubulin	28	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Approval	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	28	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Approval	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	28	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Approval	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	28	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Approval	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	28	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Approval	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	28	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Approval	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	28	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Approval	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	28	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Approval	https://conductscience.org/library/genes/81027	Drugs and targets
TUBB2A	Tubulin	28	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Approval	https://conductscience.org/library/genes/7280	Drugs and targets

1 to 10 of 490

See all 490 targets

Trials381

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 15 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02517398	MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors	Phase 1	600	2024-05-03	Solid Tumors	BINTRAFUSP ALFA	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT02526017	Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers	Phase 1	313	2022-03-09	Advanced Solid Tumors, Head and Neck Cancer, Pancreatic Cancer, Ovarian Cancer, Renal Cell Carcinoma, Malignant Glioma, Non-small Cell Lung Cancer	CABIRALIZUMAB, NIVOLUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT02598960	An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.	Phase 1/2	295	2023-03-06	Solid Tumors	BMS-986156, NIVOLUMAB	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT00648648	A Dose Escalation Study of Adavosertib (MK-1775) in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001)	Phase 1	206	2019-04-05	Solid Tumors	ADAVOSERTIB, CARBOPLATIN, CISPLATIN, GEMCITABINE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT00531284	Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma	Phase 1/2	184	2015-12-09	Ovarian Cancer, Renal Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Solid Tumors, Multiple Myeloma, Lymphoma	CARFILZOMIB	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT00982865	Trial of MSC1936369B in Subjects With Solid Tumors	Phase 1	182	2018-10-23	Solid Tumors, Cancer	PIMASERTIB	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT00996892	Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors	Phase 1	178	2016-12-30	Solid Tumors	COBIMETINIB, PICTILISIB	Open Targets' reading of its record	ClinicalTrials.gov
NCT03010176	Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)	Phase 1	156	2024-02-26	Solid Tumors, Lymphoma	PEMBROLIZUMAB, ULEVOSTINAG	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT03314935	A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors	Phase 1/2	149	2023-12-07	Biliary Tract Cancer (BTC), Colorectal Cancer (CRC), Endometrial Cancer, Gastroesophageal Cancer (GC), Ovarian Cancer, Solid Tumors	CISPLATIN, FLUOROURACIL, GEMCITABINE, LEUCOVORIN CALCIUM, NUMIDARGISTAT, OXALIPLATIN, PACLITAXEL	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT02711137	Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies	Phase 1/2	137	2022-04-28	Solid Tumors	ABIRATERONE, AZACITIDINE, GEMCITABINE, INCB-057643, PACLITAXEL, RUCAPARIB, RUXOLITINIB	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov

1 to 10 of 381

See all 381 trials

Comparisons in its trials27

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Rucaparib Cohort A vs Rucaparib Cohort B: Number of Participants Experiencing Treatment-emergent Adverse Events	63 of 63	20 of 20	83	NCT04171700	Trial comparisons
Rucaparib Cohort A vs Rucaparib Cohort B: deaths from any cause	23 of 63	10 of 20	83	NCT04171700	Trial comparisons
Rucaparib Cohort A vs Rucaparib Cohort B: serious adverse events	13 of 63	5 of 20	83	NCT04171700	Trial comparisons
Rucaparib Cohort A vs Rucaparib Cohort B: Best Overall Response Rate by Investigator	9 of 61	2 of 20	81	NCT04171700	Trial comparisons
Segment I: Continuous Dosing Regimens vs Segment II: Intermittent Dosing Regimens: Objective Response Rate	7 of 54	2 of 19	73	NCT02762981	Trial comparisons
Segment I: Continuous Dosing Regimens vs Segment II: Intermittent Dosing Regimens: Clinical Benefit Rate	13 of 54	6 of 19	73	NCT02762981	Trial comparisons
Phase I vs Phase II: Number of Participants With Adverse Events	22 of 22	19 of 19	41	NCT01100931	Trial comparisons
Phase I vs Phase II: serious adverse events	10 of 22	1 of 19	41	NCT01100931	Trial comparisons
Oxaliplatin/ Gemcitabine vs Radiation: serious adverse events	2 of 19	2 of 15	34	NCT00476086	Trial comparisons
Melanoma Cohort vs Tissue Agnostic Cohort: deaths from any cause	4 of 8	6 of 15	23	NCT04985604	Trial comparisons

1 to 10 of 27

See all 27 comparisons in its trials

Papers from its trials162

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40499147	RESULT	1	PubMed
34045232	RESULT	1	PubMed
34009501	RESULT	1	PubMed
33840050	RESULT	1	PubMed
33323462	RESULT	1	PubMed
32641320	RESULT	1	PubMed
32461347	RESULT	1	PubMed
31278692	RESULT	2	PubMed
30393943	RESULT	1	PubMed
29298798	RESULT	1	PubMed

1 to 10 of 162

See all 162 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005070

GET https://conductscience.org/api/diseases/v1/MONDO_0005070/drugs?page=2

API reference For AI assistants